Travere Therapeutics Inc
(TVTX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Sales | 30,888 | -21,269 | 28,075 | 54,167 | 48,487 |
| Cost of Goods | 4,145 | -883 | 1,114 | 2,051 | 2,138 |
| Gross Profit | 26,743 | -20,386 | 26,961 | 52,116 | 46,349 |
| Operating Expenses | 124,257 | 84,359 | 109,679 | 117,618 | 112,617 |
| Operating Income | -97,369 | -105,628 | -82,604 | -65,451 | -66,130 |
| Interest Expense | 2,850 | 2,698 | 2,829 | 2,972 | 2,515 |
| Other Income | 3,733 | 3,987 | 1,515 | 1,444 | -7,274 |
| Pre-tax Income | -96,486 | -104,339 | -83,918 | -66,979 | -75,919 |
| Income Tax | 78 | 63 | 145 | 53 | 52 |
| Net Income Continuous | -96,564 | -104,402 | -84,063 | -67,032 | -75,971 |
| Net Income Discontinuous | 10,233 | 38,579 | 14,407 | N/A | N/A |
| Net Income | $-86,331 | $-65,823 | $-69,656 | $-67,032 | $-75,971 |
| EPS Basic Total Ops | -1.27 | -1.03 | -1.09 | -1.05 | -1.20 |
| EPS Basic Continuous Ops | -1.42 | -1.63 | -1.31 | -1.05 | -1.20 |
| EPS Basic Discontinuous Ops | 0.15 | 0.61 | 0.22 | N/A | N/A |
| EPS Diluted Total Ops | -1.27 | -1.03 | -1.09 | -1.05 | -1.20 |
| EPS Diluted Continuous Ops | -1.42 | -1.63 | -1.31 | -1.05 | -1.20 |
| EPS Diluted Discontinuous Ops | 0.15 | 0.61 | 0.22 | N/A | N/A |
| EBITDA(a) | $-90,749 | $-98,717 | $-83,969 | $-56,448 | $-59,038 |